ZHEJIANG NOVUS
PharmaZHEJIANG NOVUS is a pharmaceutical company focused on Infectious Disease, Dermatology.
ZHEJIANG NOVUS's Key Drugs
ZHEJIANG NOVUS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ZHEJIANG NOVUS's Recent FDA Approvals
New NDA/BLA approvals for ZHEJIANG NOVUS over the last two years — novel drugs only, excluding generics and label supplements.
ZHEJIANG NOVUS's Therapeutic Areas
ZHEJIANG NOVUS's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZHEJIANG NOVUS's Top Competitors
ZHEJIANG NOVUS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ZHEJIANG NOVUS Pipeline Snapshot
Active clinical trials for ZHEJIANG NOVUS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-01-20
- Latest
- 2026-05-05
- Applications
- 2